January 2023 in “National journal of physiology, pharmacy and pharmacology” This study of South Indian patients with autoimmune rheumatic diseases using low-dose methotrexate reported that while mild adverse effects such as hair loss and nausea were common, serious events like cytopenia were less frequent, and folic acid supplementation significantly reduced their prevalence.
This study, involving patients with early rheumatoid arthritis, found that treatment regimens combining methotrexate and glucocorticoids, with or without initial high-dose methylprednisolone, showed higher remission rates over one year compared to methotrexate or leflunomide alone, and all regimens were generally well-tolerated.
June 2016 in “Annals of the rheumatic diseases” This study found that methotrexate, when administered according to current recommendations, effectively manages rheumatoid arthritis for many patients in Poland, although regular monitoring is necessary due to possible adverse effects.
February 2019 in “PubMed” This study found that 29.4% of patients treated with methotrexate for non-hair-related conditions experienced increased hair loss, with more frequent reports among women.
June 2019 in “Poster presentations” This study found that low dose methotrexate did not increase hair loss in rheumatoid arthritis patients compared to healthy controls, and many patients even showed a reduction in hair fall over the short term.
